Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

Urgent action needed to stop 500 preventable deaths

A new report predicts rheumatic heart disease (RHD) will lead to over 500 preventable deaths and cost the Australian health system $317 million by 2031 if no further action to tackle the disease is taken.

News & Events

Bupa pledges half a million dollars to end rheumatic heart disease

Researchers will extend a unique community-led project to end rheumatic heart disease in Aboriginal communities, thanks to nearly half a million dollars in funding from Bupa.

News & Events

RHD a notifiable condition

Western Australian doctors are now required by law to report all cases of rheumatic heart disease.

Research

Development of Group A streptococcal vaccines: an unmet global health need

This review provides an update on the current status of Group A Streptococcus vaccine development, & describes global efforts to accelerate the development...

Research

Disparity in Mortality From Rheumatic Heart Disease in Indigenous Australians

This study was undertaken to provide a comprehensive examination of rheumatic heart disease mortality rates and trends in Indigenous Australians.

Research

Treating trade: the case for clinical engagement with regional trade agreements

The global burden of non-communicable diseases (NCDs) continues to grow. Although developing settings face fastest growth in incidence, no country is exempt.

Research

The stark reality of rheumatic heart disease

This editorial refers to ‘Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart...

Research

The case for global investment in rheumatic heart-disease control

The review built a case for extending simple and cost–effective measures to all countries. Had these recommendations been put into action, significant...

Research

Group A streptococcal vaccines: Paving a path for accelerated development

Vaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades.

Research

Progress toward a global Group A streptococcal vaccine

The desire for an effective vaccine arises from the large burden of disease caused by the bacterium, particularly rheumatic fever and rheumatic heart disease.